Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Coherus Posts 94% Pegfilgrastim Margin Ahead Of Royalties To Amgen

Executive Summary

Coherus has achieved a 94% gross margin on its US sales of biosimilar pegfilgrastim. And while a litigation settlement with Amgen will dilute the margin a little, the biosimilars developer is confident it can keep the margin north of 90%.

You may also be interested in...

Coherus Will Launch US Lucentis Biosimilar By 2021

Buoyed by the success of its Udenyca pegfilgrastim biosimilar, Coherus has struck a deal with Bioeq to acquire commercialization rights to its biosimilar version of Lucentis (ranibizumab) in the US, eyeing a launch date of 2021.

Coherus Set Sights On Taking Fifth Of US Pegfilgrastim Market

Having made a strong start with sales of over $120m in its first six months on the market, Coherus believes its Udenyca biosimilar could end 2019 with more than a fifth of the US pegfilgrastim market by volume.

Coherus Fends Off Amgen’s Pegfilgrastim Purification Patent Case

Coherus’ manufacturing process for its Udenyca pegfilgrastim biosimilar does not infringe a US purification patent held by Amgen, the US Court of Appeals has confirmed.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts